---
title: "Obefazimod (ABX464) in Ulcerative colitis: Calcineurin inhibitors"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Calcineurin inhibitors. Topics: Rescue therapy in acute severe ulcerative colitis: ACG 2025, Tacrolimus in steroid-refractory disease: ACG 2025, Cyclosporine compared with infliximab: ECCO 2026, Third-line sequential rescue therapy: ECCO 2026, and 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/calcineurin-inhibitors"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Calcineurin inhibitors

<a id="heading-2.2.2.1.10"></a>

## 2.2.2.1.10 Calcineurin Inhibitors

<a id="topic-2.2.2.1.10-1"></a>

### Rescue therapy in acute severe ulcerative colitis: ACG 2025

> “In patients with ASUC failing to adequately respond to intravenous corticosteroids (IVCS) by 3 days, we recommend medical rescue therapy with infliximab or cyclosporine (Strong recommendation, moderate quality of evidence).”
> “In patients with ASUC who achieve remission with cyclosporine treatment, we suggest maintenance of remission with thiopurines (Conditional recommendation, low quality of evidence).”
> “In patients with ASUC, the choice between infliximab and cyclosporine should be based on provider experience with the agent, history of prior failure of immunomodulator or anti-TNF therapy, and serum albumin.”
> “By contrast, because cyclosporine is used less frequently and only at select centers, its use in steroid-refractory colitis should be restricted to providers who are familiar with dosing, monitoring trough concentrations, and managing adverse effects.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.10-2"></a>

### Tacrolimus in steroid-refractory disease: ACG 2025

> “Tacrolimus is a calcineurin inhibitor that has been examined in the treatment of steroid-refractory UC in both children and adults. In a double-blind placebo-controlled trial of 62 patients, the clinical response rate at week 2 was 50% with tacrolimus compared with 13% with placebo (P = 0.003) (178).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.10-3"></a>

### Cyclosporine compared with infliximab: ECCO 2026

> “We recommend either cyclosporine or infliximab as rescue therapy in patients with steroid-refractory acute severe ulcerative colitis [strong recommendation, high certainty of evidence] [Agreement: 100%]”
> “Colectomy rates at day 98 were 17% in the infliximab group versus 21% in the cyclosporine group; the differences were not statistically significant.”
> “Colectomy rates were 30.9% and 34.9% in the infliximab group versus 29.1% and 38.5% in the cyclosporine group at 1 and 5 years, respectively [P = .97].”
> “In summary, the available evidence supports the use of either infliximab or cyclosporine as rescue therapy in ASUC refractory to IV corticosteroids, with comparable colectomy rates, safety profiles, and QoL outcomes across trials. However, infliximab was associated with significantly greater short-term endoscopic remission.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.10-4"></a>

### Third-line sequential rescue therapy: ECCO 2026

> “We suggest that the use of a third-line sequential rescue therapy with infliximab, a calcineurin inhibitor, or a Janus kinase inhibitor may be considered in highly selected patients with acute severe ulcerative colitis who are refractory to intravenous corticosteroids and a second-line treatment [infliximab or calcineurin inhibitor] in experienced multidisciplinary centers and after discussion of surgical options and potential risks and benefits [weak recommendation, low certainty of evidence] [Agreement: 100%]”
> “In a recent systematic review that included 23 studies, third-line rescue therapy resulted in avoidance of colectomy in 53% of patients with ASUC [95% CI: 47%–58%].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.10-5"></a>

### Calcineurin inhibitors prohibited during obefazimod open-label maintenance

> “The use of biologics (eg, TNF-α inhibitors, vedolizumab, ustekinumab), JAK inhibitors, cyclosporin, and tacrolimus was prohibited during the study.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
